Novartis cuts 183 NJ jobs; Pfizer completes Ferrosan Consumer Health buyout;

@FiercePharma: Guess this was inevitable: Senators start poking around in Pfizer's Lipitor-at-generic-price deals - NYT. Article | Follow @FiercePharma

> Novartis ($NVS) is cutting 183 jobs in New Jersey as part of its ongoing restructuring of clinical development work. News

> Pfizer ($PFE) has wrapped up its acquisition of Ferrosan Consumer Health, the Danish company that sells skincare products and dietary supplements in Russia, Europe and the Nordic countries. Story

> GlaxoSmithKline's ($GSK) new definition of core earnings, which brings it into line with its Big Pharma peers, could give the company a lift, Reuters says. Article

> Eli Lilly ($LLY) spent $2.3 million lobbying the U.S. government during the third quarter, focusing on patent reform, trade and hospital discounts. News

> Russian drugmakers are appealing to Prime Minister Vladimir Putin on pricing policies that prevent their raising the cost of products, despite inflation in labor, raw materials and energy. Story

> India's Vivimed Labs bought Uquifa, which makes active pharmaceutical ingredients in Spain and Mexico. Report

> Eisai ($ESALY) is set to launch a new formulation of the anti-coagulant warfarin in Japan. More

> Merck KGaA tapped Friederike Rotsch as its new head auditor and Isabel De Paoli to lead corporate strategy, both reporting to Chairman Karl-Ludwig Kley. Piece

Biotech News

@FierceBiotech: Study: MDs often asked for alternative vaccine schedules. Item | Follow@FierceBiotech

@RyanMFierce: Dutch-Belgian biotech arGEN-X (antibody discovery) bagged $37M in B round co-led by OrbiMed and Seventure PR. Release | Follow@RyanMFierce

@MaureenFierce: Novartis MS Pill Gilenya Rejected by U.K. Health-Cost Agency. Report | Follow @MaureenFierce

> MacroGenics pockets $20M in $450M deal with Servier. Report

Vaccines News

> Misconceptions stymie HIV vaccine trials. Report

> For stronger vaccines, pay attention to carbohydrates. Article

> China preps for big push into vaccine market. News

> Study: MDs often asked for alternative vaccine schedules. Item

Manufacturing News

> Police net $8 million in counterfeit drugs. News

> Ranbaxy drama shows manufacturing impact on pharma business. Report

> Fujifilm presses biosimilars ambition. Item

> GSK a step closer to becoming energy provider. News

> Analyst: Hospira manufacturing woes possibly systemic. Report

> Contamination concern rises about CMOs. News

And Finally... HIV treatment in the young is becoming more complicated, with children as young as 5 resistant to AIDS meds. Report

Suggested Articles

BMS’s Opdivo has plenty of competition in its current bladder cancer indication—so it’s hoping to strike out on its own in a new area of the disease.

The Japanese approval, under the brand name Jyseleca, came a month after an FDA complete response letter that asked Gilead for more data.

The Trump Administration has opened the doors for Florida and other states to import prescription drugs from Canada—despite industry objections.